Evidence map›Paper›PMID 24415980›Full record

ArticleBreast care (Basel, Switzerland)2013

Is routine audiometric evaluation necessary in gynaecologic tumour patients undergoing chemotherapy?

Ayotunde J Fasunla, Nadia Harbeck, Barbara Schmalfeld, Sabina Berktold, Christina Böhner, Walter Hundt, Petra Wolf, Silke Steinbach

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast care (Basel, Switzerland), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Ayotunde J FasunlaDepartment of Otorhinolaryngology, Philipps-University, Marburg, Germany ; Department of Otorhinolaryngology, College of Medicine, University of Ibadan and University College Hospital, Ibadan, Nigeria, Germany.
Nadia HarbeckBreast Centre, Ludwig-Maximilians University, Munich, Germany.
Barbara SchmalfeldDepartment of Obstetrics and Gynaecology, Women's Hospital Rechts der Isar, Germany.
Sabina BerktoldDepartment of Obstetrics and Gynaecology, Women's Hospital Rechts der Isar, Germany.
Christina BöhnerDepartment of Obstetrics and Gynaecology, Women's Hospital Rechts der Isar, Germany.
Walter HundtDepartment of Radiology, Philipps-University, Marburg, Germany.
Petra WolfInstitute of Medical Statistics and Epidemiology, Hospital Rechts der Isar, Technical University Munich, Germany.
Silke SteinbachDepartment of Otorhinolaryngology, Philipps-University, Marburg, Germany.
Philipps University of Marburg · DEKlinikum rechts der Isar · DELudwig-Maximilians-Universität München · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOur objective was to assess the auditory function of gynaecological tumour patients who had received cytotoxic agents and to determine their associated risk of ototoxicity. PATIENTS AND

methods87 patients who had undergone chemotherapy for gynaecological malignancies were investigated. Of these patients, 79% had breast cancer, and 14% ovarian cancer. All of the patients had a subjective assessment of their hearing function on a visual analogue scale. Audiometric tests were performed before and at 9 weeks, 18 weeks and 3 months after completion of chemotherapy.

resultsThe age of the patients ranged from 32 to 71 years (mean age of 53.5 ± 10.5 years). The average subjective rating of the patients' hearing function was 83.0 ± 17.2 before and 84.8 ± 16.9 3 months after completion of chemotherapy. No significant audiometric change at either the speech hearing frequency range (0.5-2 KHz) or high frequencies was observed in the patients after chemotherapy. There was also no significant difference in the hearing threshold of the patients who had received platinum analogue-based chemotherapy compared to non-platinum analogue-based chemotherapy.

conclusionHearing loss is uncommon in patients treated with the typical gynaecological chemotherapy protocols. Hence, routine audiometric testing in these patients is not necessary.

Indexed as

Breast cancerChemotherapyHearing functionOvarian cancer

Identifiers

PMID24415980
PMCPMC3808219
OpenAlexW1995519925

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.